Citations

Clear

79 citation(s) found for "Shang, Lu".

How to Best Protect People With Diabetes From the Impact of SARS-CoV-2: Report of the International COVID-19 and Diabetes Summit
Zhang, Jennifer Y. , Shang, Trisha , Ahn, David , Chen, Kong Y. , Coté, Gerard L. , Espinoza, Juan , Mendez, Carlos E. , Spanakis, Elias K. , Thompson, Bithika , Wallia, Amisha , Wisk, Lauren E. , Kerr, David , Klonoff, David C. , Chen, Kong , Coté, Gerard , Espinoza, Juan , Shang, Trisha , Zhang, Jennifer Y , Ahn, David T

Mayo Clinic

Journal of Diabetes Science and Technology | January 21, 2021 | Volume: 15 | Issue: 2 | Pages: 478-514

10.1177/1932296820978399 | PMID 33476193 Get It

The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus has rapidly involved the entire world and exposed the pressing need for collaboration between public health and other stakeholders from the clinical, scientific, regulatory, pharmaceutical, and medical device and technology communities. To discuss how to best protect people with diabetes from serious outcomes from COVID-19, Diabetes Technology Society, in collaboration with Sansum Diabetes Research Institute, hosted the “International COVID-19 and Diabetes Virtual Summit” on August 26-27, 2020. This unique, unprecedented real-time conference brought together physicians, scientists, government officials, regulatory experts, industry representatives, and people with diabetes from six continents to review and analyze relationships between COVID-19 and diabetes. Over 800 attendees logged in. The summit consisted of five sessions: (I) Keynotes, (II) Preparedness, (III) Response, (IV) Recovery, and (V) Surveillance; eight parts: (A) Background, (B) Resilience, (C) Outpatient Care, (D) Inpatient Care, (E) Resources, (F) High-Risk Groups, (G) Regulation, and (H) The Future; and 24 sections: (1) Historic Pandemics and Impact on Society, (2) Pathophysiology/Risk Factors for COVID-19, (3) Social Determinants of COVID-19, (4) Preparing for the Future, (5) Medications and Vaccines, (6) Psychology of Patients and Caregivers, (7) Outpatient Treatment of Diabetes Mellitus and Non-Pharmacologic Intervention, (8) Technology and Telehealth for Diabetes Outpatients, (9) Technology for Inpatients, (10) Management of Diabetes Inpatients with COVID-19, (11) Ethics, (12) Accuracy of Diagnostic Tests, (13) Children, (14) Pregnancy, (15) Economics of Care for COVID-19, (16) Role of Industry, (17) Protection of Healthcare Workers, (18) People with Diabetes, (19) International Responses to COVID-19, (20) Government Policy, (21) Regulation of Tests and Treatments, (22) Digital Health Technology, (23) Big Data Statistics, and 24) Patient Surveillance and Privacy. The two keynote speeches were entitled (1) COVID-19 and Diabetes—Meeting the Challenge and (2) Knowledge Gaps and Research Opportunities for Diabetes and COVID-19. While there was an emphasis on diabetes and its interactions with COVID-19, the panelists also discussed the COVID-19 pandemic in general. The meeting generated many novel ideas for collaboration between experts in medicine, science, government, and industry to develop new technologies and disease treatment paradigms to fight this global pandemic.
Early Selective Vulnerability of the CA2 Hippocampal Subfield in Primary Age-Related Tauopathy
Walker, Jamie M. , Richardson, Timothy E. , Iida, Megan A., Foong, Chan, Shang, Ping , Attems, Johannes , Ayalon, Gai , Beach, Thomas G. , Bigio, Eileen H. , Budson, Andrew E. , Cairns, Nigel J. , Corrada, María M. , Cortés, Etty , Flanagan, Margaret E. , Franklin, Erin , Gearing, Marla , Glass, Jonathan D. , Hansen, Lawrence A. , Haroutunian, Vahram , Kawas, Claudia H. , Keene, C. Dirk , Kofler, Julia , Kovács, Gábor G. , Lee, Edward B. , Lutz, Mirjam I. , Masliah, Eliezer , McKee, Ann C. , Mesulam, M.‐Marsel, Nelson, Peter T. , Perrin, Richard J. , Pham, Thao, Purohit, Dushyant P. , Sakai, Kenji , Sano, Mary , Stein, Thor D. , Teich, Andrew F. , Trojanowski, John Q. , Troncoso, Juan C. , Vonsattel, Jean-Paul G., Weıntraub, Sandra , Woltjer, Randall L. , Yamada, Masahito , Yu, Lei , Crary, John F. , Seshadri, Sudha , Murray, Melissa, Seshadri, Sudha , Kovacs, Gabor G , Murray, Melissa E , Teich, Andrew F , Lee, Edward B , Farrell, Kurt , Dickson, Dennis W. , Fischer, Peter A. , Hof, Patrick R. , Honig, Lawrence S. , Mao, Qinwen , McMillan, Corey T. , Murray, Melissa E. , Poon, Wayne W. , Rissman, Robert A. , Schneider, Julie A. , Wolk, David A. , White, Charles L. , Flanagan, Margaret E

Mayo Clinic

Journal of Neuropathology & Experimental Neurology | December 23, 2020 | Volume: 80 | Issue: 2 | Pages: 102-111

10.1093/jnen/nlaa153 | PMID 33367843 Get It

Abstract Primary age-related tauopathy (PART) is a neurodegenerative entity defined as Alzheimer-type neurofibrillary degeneration primarily affecting the medial temporal lobe with minimal to absent amyloid-β (Aβ) plaque deposition. The extent to which PART can be differentiated pathoanatomically from Alzheimer disease (AD) is unclear. Here, we examined the regional distribution of tau pathology in a large cohort of postmortem brains (n = 914). We found an early vulnerability of the CA2 subregion of the hippocampus to neurofibrillary degeneration in PART, and semiquantitative assessment of neurofibrillary degeneration in CA2 was significantly greater than in CA1 in PART. In contrast, subjects harboring intermediate-to-high AD neuropathologic change (ADNC) displayed relative sparing of CA2 until later stages of their disease course. In addition, the CA2/CA1 ratio of neurofibrillary degeneration in PART was significantly higher than in subjects with intermediate-to-high ADNC burden. Furthermore, the distribution of tau pathology in PART diverges from the Braak NFT staging system and Braak stage does not correlate with cognitive function in PART as it does in individuals with intermediate-to-high ADNC. These findings highlight the need for a better understanding of the contribution of PART to cognitive impairment and how neurofibrillary degeneration interacts with Aβ pathology in AD and PART.
Mechanical ventilation in Guillain–Barré syndrome
Shang, Pei , Zhu, Mingqin , Feng, Jiachun , Zhou, Chunkui , Zhang, Hongliang , Feng, Jiachun , Zhang, Hong-Liang , Shang, Pei , Baker, Matthew

Mayo Clinic

Expert Review of Clinical Immunology | October 28, 2020 | Volume: 16 | Issue: 11 | Pages: 1053-1064

10.1080/1744666x.2021.1840355 | PMID 33112177 Get It

Continuous Glucose Monitors and Automated Insulin Dosing Systems in the Hospital Consensus Guideline
Galindo, Rodolfo J. , Rushakoff, Robert J , Basu, Ananda , Lohnes, Suzanne, Nichols, James H. , Spanakis, Elias K. , Espinoza, Juan , Palermo, Nadine E. , Awadjie, Dessa Garnett, Bak, Leigh B., Buckingham, Bruce A. , Freckmann, Guido , Hovorka, Roman , Mathioudakis, Nestoras , Newman, Tonya, O’Neal, David N. , Rickert, Michaela , Wallia, Amisha , Shang, Trisha , Zhang, Jennifer Y. , Han, Julia , Klonoff, David C. , Nichols, James H , Spanakis, Elias K , Espinoza, Juan , Cook, Curtiss B. , Freckmann, Guido , Heinemann, Lutz , O'Neal, David N , Sacks, David B , Shang, Trisha , Zhang, Jennifer Y , Klonoff, David C , Galindo, Rodolfo J , Hovorka, Roman , Mathioudakis, Nestoras N , Buckingham, Bruce , Umpierrez, Guillermo E. , Heinemann, Lutz , Seley, Jane Jeffrie

Mayo Clinic

Journal of Diabetes Science and Technology | September 28, 2020 | Volume: 14 | Issue: 6 | Pages: 1035-1064

10.1177/1932296820954163 | PMID 32985262 Get It

This article is the work product of the Continuous Glucose Monitor and Automated Insulin Dosing Systems in the Hospital Consensus Guideline Panel, which was organized by Diabetes Technology Society and met virtually on April 23, 2020. The guideline panel consisted of 24 international experts in the use of continuous glucose monitors (CGMs) and automated insulin dosing (AID) systems representing adult endocrinology, pediatric endocrinology, obstetrics and gynecology, advanced practice nursing, diabetes care and education, clinical chemistry, bioengineering, and product liability law. The panelists reviewed the medical literature pertaining to five topics: (1) continuation of home CGMs after hospitalization, (2) initiation of CGMs in the hospital, (3) continuation of AID systems in the hospital, (4) logistics and hands-on care of hospitalized patients using CGMs and AID systems, and (5) data management of CGMs and AID systems in the hospital. The panelists then developed three types of recommendations for each topic, including clinical practice (to use the technology optimally), research (to improve the safety and effectiveness of the technology), and hospital policies (to build an environment for facilitating use of these devices) for each of the five topics. The panelists voted on 78 proposed recommendations. Based on the panel vote, 77 recommendations were classified as either strong or mild. One recommendation failed to reach consensus. Additional research is needed on CGMs and AID systems in the hospital setting regarding device accuracy, practices for deployment, data management, and achievable outcomes. This guideline is intended to support these technologies for the management of hospitalized patients with diabetes.
Modified Use of Costal Cartilage in Asians for the Correction of Nostril Asymmetry in Unilateral Secondary Cleft Lip Nasal Deformity
Zhang, Zhenyu , Huang, Tony Chieh‐Ting , He, Yinhai , Li, Zhengyong , Chen, Junjie , Qing, Yong , He, Yinhai, Shang, Li , Cen, Ying

Mayo Clinic

Annals of Plastic Surgery | July 30, 2020 | Volume: 86 | Issue: 2 | Pages: 175-181

10.1097/sap.0000000000002503 | PMID 32756249 Get It

Background Weak alar cartilage and lack of soft tissue on the cleft side are considered to be the main critical factors leading to the asymmetry of bilateral nostrils. The costal cartilage can provide strong structural support and can be used to maintain long-term stability of nostril shape after surgical correction. With the advancement in rhinoplasty techniques, the application and understanding of costal cartilage in cleft lip nasal deformity is still on going. Herein, we present our technique of applying costal cartilage to provide nostril support and correct asymmetry in Asian patients with unilateral secondary cleft lip nasal deformity. Methods Ninety-seven patients who underwent nostril asymmetry correction from January 1, 2013, to October 31, 2018, were analyzed retrospectively. Modified integrative alar cartilage strut and diced nostril augmentation with costal cartilage were implemented to improve the collapsed and flat cleft-side nostril. The release and restoration of muscle and bone were also performed when required. Surgical outcomes were analyzed based on the comparison of nostril parameters, the shape and contour, and symmetry of bilateral nostrils after surgery. During postoperative follow-up, the patients' satisfactions with the corrective outcomes were also investigated. Results All patients received the corrective operations with complete survival of all implanted cartilages. The nostril width was narrower in postoperative group (P < 0.05). The nostril height and long axis angle were higher postoperatively (P < 0.05). After correction, the proportion of moderate type increased from 13.4% to 80.4%, whereas the proportion of horizontal type decreased from 86.6% to 17.5%. The symmetry score on the nostril parameters manifested the rate of high score (AS >3) in postoperative groups were 84.5%, 93.8%, and 87.6% for width, height, and angle of the long axis, respectively. They were higher compared with those of preoperative group (0%). More than 95% of the patients were satisfied with the overall aesthetic outcome of the surgery. Conclusions Through ameliorating its constructive technology and optimizing its filling form, the modified use of costal cartilage displayed excellent correction effects in the width, height, and long axis angle asymmetry of Asian patients' nostril. Precise and comprehensive rhinoplasty technique is the cornerstone for achieving satisfactory long-term aesthetic outcomes, especially in severe cases, such as secondary cleft lip nasal deformity.
Call to action regarding the vascular‐bipolar link: A report from the Vascular Task Force of the International Society for Bipolar Disorders
Goldstein, Benjamin I. , Bond, David J. , Chen, Pao‐Huan , Fagiolini, Andrea , Hájek, Tomáš , Hatch, Jessica, Prieto, Miguel L. , Sylvia, Louisa G. , Tsai, Shang‐Ying , Kcomt, Andrew , Fiedorowicz, Jess G. , Bond, David J , Chen, Pao-Huan , Fagiolini, Andrea , Hajek, Tomas , McIntyre, Roger S , Prieto, Miguel L , Tsai, Shang-Ying , Fiedorowicz, Jess G , Baune, Bernhard , Eyler, Lisa T. , Gomes, Fabiano A. , McElroy, Susan L. , McIntyre, Roger S. , Goldstein, Benjamin I

Mayo Clinic

Bipolar Disorders | May 1, 2020 | Volume: 22 | Issue: 5 | Pages: 440-460

10.1111/bdi.12921 | PMID 32356562 Get It

Abstract Objectives The association of bipolar disorder with early and excessive cardiovascular disease was identified over a century ago. Nonetheless, the vascular‐bipolar link remains underrecognized, particularly with regard to how this link can contribute to our understanding of pathogenesis and treatment. Methods An international group of experts completed a selective review of the literature, distilling core themes, identifying limitations and gaps in the literature, and highlighting future directions to bridge these gaps. Results The association between bipolar disorder and vascular disease is large in magnitude, consistent across studies, and independent of confounding variables where assessed. The vascular‐bipolar link is multifactorial and is difficult to study given the latency between the onset of bipolar disorder, often in adolescence or early adulthood, and subsequent vascular disease, which usually occurs decades later. As a result, studies have often focused on risk factors for vascular disease or intermediate phenotypes, such as structural and functional vascular imaging measures. There is interest in identifying the most relevant mediators of this relationship, including lifestyle (eg, smoking, diet, exercise), medications, and systemic biological mediators (eg, inflammation). Nonetheless, there is a paucity of treatment studies that deliberately engage these mediators, and thus far no treatment studies have focused on engaging vascular imaging targets. Conclusions Further research focused on the vascular‐bipolar link holds promise for gleaning insights regarding the underlying causes of bipolar disorder, identifying novel treatment approaches, and mitigating disparities in cardiovascular outcomes for people with bipolar disorder.
FcRL5 as a Target of Antibody-Drug Conjugates for the Treatment of Multiple Myeloma.
Polson, Andrew G. , Elkins, Kristi , Lau, Jeffery, Go, Mary Ann T. , Scales, Suzie J. , Yu, Shang‐Fan , Chesi, Marta , Ebens, Allen , Zheng, Bing , Bergsagel, P. Leif

Mayo Clinic

Blood | October 13, 2019 | Volume: 114 | Issue: 22 | Pages: 3836-3836

10.1182/blood.v114.22.3836.3836 Get It

Abstract Abstract 3836 Poster Board III-772 Antibody-drug conjugates (ADCs), potent cytotoxic drugs linked to antibodies via specialized chemical linkers, provide a means to increase the effectiveness of chemotherapy by targeting the drug to neoplastic cells while reducing side effects. Target selection is a key component to the success of an ADC. In addition to expression on the tumor, the target should have limited expression on normal tissues. The most prevalent and best-studied surface antigens on multiple myeloma (MM) cells, CD138, CD38, CD72, and CD56, all have relatively broad expression patterns that may lead to target-dependent toxicities with ADCs. We have previously shown that FcRL5/FcRH5/IRTA2 is expressed only on B-cells and plasma cells. Here we show that FcRL5 is expressed on the surface of MM cells from 85% of patients and thus could be a target for antibody and ADC treatments of MM. As experience in humans with anti-CD20 antibodies suggests that depletion of B-cells does not present a major safety issue, FcRL5 appears to have an excellent expression pattern as an ADC target for MM. Internalization of target antigens is known to increase the efficacy of ADCs and we found that FcRL5 is internalized upon antibody binding, an ideal trait. We made two different ADCs consisting of anti-FcRL5 antibodies 1) conjugated through cysteines to monomethylauristatin E (MMAE) by a maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl (MC-vcPAB) linker that is designed to be cleaved by cathepsins (Anti-FcRL5-MC-vcPAB-MMAE); and 2) conjugated via lysines to the maytansinoid DM4 through a disulified linker designed to be cleaved by reducing conditions (anti-FcRL5-SPDB-DM4). These ADCs were tested for cell killing in vitro and in xenograft studies using OPM2 cells stably expressing FcRL5. While unconjugated anti-FcRH5 and control ADCs were not effective, anti-FcRL5-MC-vcPAB-MMAE and anti-FcRL5-SPDB-DM4 were effective at killing this MM cell line both in vitro and in vivo. Furthermore, the anti-FcRL5-SPDB-DM4 conjugate was effective in a SCID-rabbit bone model of MM using the LD cell line. These data suggest that FcRL5 ADCs could be an effective treatment for MM. Disclosures: Polson: Genentech, Inc.: Employment, Equity Ownership. Zheng:Genentech, Inc.: Employment, Equity Ownership. Elkins:Genentech, Inc.: Employment, Equity Ownership. Lau:Genentech, Inc.: Employment, Equity Ownership. Go:Genentech, Inc.: Employment, Equity Ownership. Scales:Genentech, Inc.: Employment, Equity Ownership. Yu:Genentech, Inc.: Employment, Equity Ownership. Chesi:Genentech, Inc.: Consultancy; Amgen: Consultancy; Celgene: Consultancy; Merck: Research Funding. Bergsagel:Genentech, Inc.: Consultancy; Amgen: Consultancy; Celgene: Consultancy; Merck: Research Funding. Ebens:Genentech, Inc.: Employment, Equity Ownership, Patents & Royalties.
CD40 Pathway Activation Status Predicts Response to CD40 Targeted Therapy in Diffuse Large b-Cell Lymphoma.
Dornan, David, Burington, Bart, Peng, Yue , Shi, Xiaoyan , Lau, Jeffrey , Yu, Shang‐Fan , Vos, Sven de , Ansell, Stephen M. , Forero‐Torres, Andres , Koeppen, Hartmut , Yang, Teddy, Du, Changchun, Elkins, Kristi , Polson, Andrew G. , Offringa, Rienk , Whiting, Nancy, Ebens, Allen , Advani, Ranjana H. , Yu, Nancy , Modrušan, Zora

Mayo Clinic

Blood | October 12, 2019 | Volume: 114 | Issue: 22 | Pages: 2721-2721

10.1182/blood.v114.22.2721.2721 Get It

Abstract Abstract 2721 Poster Board II-697 The role of the CD40 pathway in B-cell cancers is rather enigmatic due to having polar opposite roles in tumor biology. Stimulation of the CD40 receptor can reduce cell viability of NHL cell lines and xenograft tumor models, whereas, in sharp contrast, constitutive CD40 stimulation can actually promote proliferation of NHL cell lines, as well as drive lymphomagenesis and transformation of primary B-cells. Therefore, targeting the CD40 pathway has been challenging due to a knowledge gap in understanding the factors that may dictate a pro- or anti-tumor role. To address this directly, we employed a large panel of NHL cell lines and xenografts models to simulate a patient population and to define the molecular parameters to test in the context of clinical trials. Using baseline gene expression profiling, we found that the in vitro activity of an antibody that stimulates the CD40 pathway, Dacetuzumab (SGN-40), correlated strikingly with a transcriptional profile that was representative of an inactive CD40 pathway. Resistant cells, on the other hand, displayed a transcriptional profile indicative of an activated CD40 pathway. Consistent with these observations, constitutive phosphorylation of ERK, a node downstream of CD40 signaling, was present predominantly in cell lines that were resistant to Dacetuzumab. Fifteen genes, based on their association with in vitro activity and their biology as components of the CD40 network, were selected as a classifier from these pre-clinical data and independently tested in a panel of cell lines and xenografts models. Testing the selected gene classifier by qRT-PCR from baseline fixed tumor tissue of 39 patients treated with Dacetuzumab in phase I and II clinical trials revealed the ability to predict sensitivity in patients, as determined by tumor shrinkage >10%, with an overall accuracy of 80%. Consistent with the observed tumor shrinkage, the classifier positive, predicted to respond to Dacetuzumab, patients also exhibited a prolonged progression free survival (PFS) compared to classifier negative patients, predicted not to respond to Dacetuzumab (HR = 0.23, p = 0.001). Finally, using a novel microarray approach to genome-wide expression profiling on fixed tumor tissue revealed that CD40 pathway activation was indeed an important predictor of response. Overall, these data suggest that sensitivity to Dacetuzumab can be predicted by pre-determining the CD40 pathway activation status of tumors. Disclosures: Dornan: Genentech, Inc.: Employment, Equity Ownership. Burington:Genentech, Inc.: Employment, Equity Ownership. Yue:Genentech, Inc.: Employment, Equity Ownership. Shi:Genentech, Inc.: Employment, Equity Ownership. Advani:Seattle Genetics, Inc.: Research Funding. Yu:Genentech, Inc.: Employment, Equity Ownership. Lau:Genentech, Inc.: Employment, Equity Ownership. Yu:Genentech, Inc.: Employment, Equity Ownership. De Vos:Seattle Genetics, Inc.: Research Funding. Forero-Torres:Seattle Genetics, Inc.: Research Funding. Modrusan:Genentech, Inc.: Employment, Equity Ownership. Koeppen:Genentech, Inc.: Employment, Equity Ownership. Yang:Genentech, Inc.: Employment, Equity Ownership. Du:Genentech, Inc.: Employment, Equity Ownership. Elkins:Genentech, Inc.: Employment, Equity Ownership. Polson:Genentech, Inc.: Employment, Equity Ownership. Offringa:Genentech, Inc.: Employment, Equity Ownership. Whiting:Seattle Genetics, Inc.: Employment, Equity Ownership. Ebens:Genentech, Inc.: Employment, Equity Ownership.
Initial skin cancer screening for solid organ transplant recipients in the United States: Delphi method development of expert consensus guidelines
Crow, Lauren , Jambusaria‐Pahlajani, Anokhi , Chung, Christina Lee , Baran, David A. , Lowenstein, Stefan E. , Abdelmalek, Mark, Ahmed, Rehana L. , Anadkat, Milan J. , Arcasoy, Selim M. , Berg, Daniel , Bibee, Kristin , Billingsley, Elizabeth M. , Black, William H., Blalock, Travis W. , Bleicher, Melissa, Brennan, Daniel C. , Brodland, David G., Brown, Mariah , Carroll, Bryan T. , Carucci, John A. , Chang, Timothy W., Chaux, George, Cusack, Carrie Ann, Dilling, Daniel F. , Doyle, Alden , Emtiazjoo, Amir , Ferguson, Nkanyezi H., Fosko, Scott W. , Fox, Matthew C., Göral, Simin , Gray, Alice , Griffin, John R., Hall, Shelley , Hanlon, Allison , Hayes, Don , Hickey, Gavin , Holtz, Jonathan E., Hopkins, R. Samuel, Hu, Jenny, Huang, Conway C. , Kapnadak, Siddhartha G. , Kraus, Edward S., Leitenberger, Justin J. , Lim, Mary Ann , Longo, María Isabel , Malik, Shahid M. , Menter, Alan , Myers, Sarah A., Neuburg, Marcy, Nijhawan, Rajiv I. , Norman, Douglas J., Otley, Clark C. , Paek, So Yeon , Parulekar, Amit , Patel, Manisha J., Patton, Timothy , Pugliano‐Mauro, Melissa , Ranganna, Karthik, Redenius, Rachel, Samie, Faramarz H. , Shin, Thuzar M. , Singer, Jonathan P. , Singh, Pooja , Soon, Seaver L. , Squires, Ronald A., Stasko, Thomas, Stein, Jennifer , Taler, Sandra J. , Thomas, Christie P. , Tokman, Sofya , Tomic, Rade , Twigg, Amanda R. , Wigger, M., Zeitouni, Nathalie C., Crow, Lauren D , Leca, Nicolae , Mallea, Jorge M. , Tomic, Rade , Singer, Jonathan P , Baran, David A , Paek, So Yeon , Ferguson, Nkanyezi , Hachem, Ramsey R. , Jiang, Shang I. Brian , Lease, Erika D. , Lee, James , Patel, Vishal Anil , Ravichandran, Ashwin Kumar , Redenius, Rachel A., Roll, Garrett Richard , Soriano, Teresa T. , Terrault, Norah A. , Arron, Sarah T. , Thomas, Christie P

Mayo Clinic

Transplant International | September 10, 2019 | Volume: 32 | Issue: 12 | Pages: 1268-1276

10.1111/tri.13520 | PMID 31502728 Get It

A case study evaluating the portability of an executable computable phenotype algorithm across multiple institutions and electronic health record environments
Pacheco, Jennifer A. , Rasmussen, Luke V. , Kiefer, Richard C. , Speltz, Peter, Carroll, Robert J. , Stallings, Sarah , Mo, Huan , Ahuja, Monika, Jiang, Guoqian , LaRose, Eric , Peissig, Peggy , Shang, Ning , Benoit, Barbara, Gainer, Vivian S., Borthwick, Kenneth M., Jackson, Kathryn , Sharma, Ambrish Kumar, Wu, Andy , Roden, Dan M. , Pathak, Jyotishman , Denny, Joshua C. , Thompson, William K. , Denny, Joshua C , Rasmussen, Luke V , Pacheco, Jennifer A , Campion, Thomas R , Wu, Andy Yizhou, Kho, Abel , Roden, Dan M.

Mayo Clinic

Journal of the American Medical Informatics Association | July 14, 2018 | Volume: 25 | Issue: 11 | Pages: 1540-1546

10.1093/jamia/ocy101 | PMID 30124903 Get It

Abstract Electronic health record (EHR) algorithms for defining patient cohorts are commonly shared as free-text descriptions that require human intervention both to interpret and implement. We developed the Phenotype Execution and Modeling Architecture (PhEMA, http://projectphema.org) to author and execute standardized computable phenotype algorithms. With PhEMA, we converted an algorithm for benign prostatic hyperplasia, developed for the electronic Medical Records and Genomics network (eMERGE), into a standards-based computable format. Eight sites (7 within eMERGE) received the computable algorithm, and 6 successfully executed it against local data warehouses and/or i2b2 instances. Blinded random chart review of cases selected by the computable algorithm shows PPV ≥90%, and 3 out of 5 sites had &gt;90% overlap of selected cases when comparing the computable algorithm to their original eMERGE implementation. This case study demonstrates potential use of PhEMA computable representations to automate phenotyping across different EHR systems, but also highlights some ongoing challenges.